Global Bare Metal Stents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Bare Metal Stents Market Analysis

The bare metal stents (BMS) market is a vital segment of the global cardiovascular device industry, used primarily in the treatment of coronary artery disease (CAD). Bare metal stents are tubular devices implanted in narrowed arteries to restore blood flow, offering significant benefits in terms of reducing restenosis (re-narrowing of arteries) compared to balloon angioplasty alone. Although drug-eluting stents (DES) have emerged as a more advanced option, BMS remains a cost-effective alternative for many patients, particularly in regions with less access to advanced healthcare technologies. The market has seen steady growth, driven by an aging global population, increasing prevalence of cardiovascular diseases, and rising awareness of heart disease treatment options.

Technological advancements in bare metal stent design, such as the development of stents with improved biocompatibility and enhanced flexibility, have contributed to their continued relevance in cardiovascular procedures. In addition, improvements in material science, such as the use of stainless steel and cobalt chromium, have helped reduce complications and improve the long-term success rate of BMS implantation. As healthcare expenditures rise and access to medical care improves, the demand for bare metal stents is expected to maintain its growth trajectory, particularly in emerging economies.

Bare Metal Stents Market Size

The global bare metal stents market size was valued at USD 9.08 billion in 2024 and is projected to reach USD 14.46 billion by 2032, with a CAGR of 5.98% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bare Metal Stents Market Trends

“Growing Use of Interleukin-6 (IL-6) Inhibitors”

The bare metal stents (BMS) market continues to expand, driven by the increasing prevalence of coronary artery disease (CAD) and the ongoing need for cost-effective treatments. One key trend in the market is the growing adoption of BMS in emerging markets due to their affordability and effectiveness in treating CAD. While drug-eluting stents (DES) have become the gold standard in many developed countries, BMS remains a preferred option in regions such as Asia-Pacific and Africa, where healthcare budgets are more constrained. For instance, in India and parts of Southeast Asia, BMS is widely used because of its lower cost compared to DES, while still offering improved outcomes over balloon angioplasty. As healthcare access improves in these regions, the demand for BMS is expected to rise. In addition, advancements in stent materials, such as the use of cobalt-chromium alloys, are enhancing stent performance, reducing restenosis rates, and improving patient outcomes, further bolstering market growth.

Report Scope and Bare Metal Stents Market Segmentation  

Bare Metal Stents Market Definition

Bare metal stents (BMS) are small, mesh-such as devices made of metal, typically stainless steel or cobalt-chromium alloys, that are used in coronary angioplasty to open narrowed or blocked blood vessels, particularly in the treatment of coronary artery disease (CAD). Unsuch as drug-eluting stents (DES), which are coated with medication to prevent restenosis (the re-narrowing of blood vessels), bare metal stents do not have any medication coating.

Bare Metal Stents Market Dynamics

Drivers

• Increasing Prevalence of Cardiovascular Diseases (CVDs)

The increasing prevalence of cardiovascular diseases (CVDs), particularly coronary artery disease (CAD), is a key driver of the bare metal stents market. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for an estimated 32% of all deaths in 2019. As CAD continues to rise, particularly among aging populations, the need for effective treatment options such as bare metal stents is intensifying. For instance, a report from the American Heart Association highlights that more than 18 million adults in the U.S. are affected by CAD, further driving the demand for interventional treatments such as stenting. Bare metal stents are often used for patients who have a lower risk of restenosis or who cannot afford drug-eluting stents, making them a cost-effective alternative. This growing demand, driven by the rising incidence of CAD, directly contributes to the market expansion of bare metal stents.

• Increasing Aging Global Population

The aging global population is significantly contributing to the growth of the bare metal stents market, as older individuals are more prone to cardiovascular conditions. According to the United Nations, the number of people aged 60 and above is expected to reach 2.1 billion by 2050, accounting for 21% of the global population. As individuals age, they are at a higher risk for developing coronary artery disease (CAD) and other heart-related conditions, which often require stenting procedures for effective management. For instance, studies show that about 15-20% of patients over 65 undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) require stents. With the prevalence of cardiovascular diseases rising among older populations, the demand for stents, including bare metal stents, is expected to surge. This demographic trend is a key driver of market growth, as stenting offers a critical solution for restoring blood flow in affected arteries, thereby improving quality of life for aging individuals.

Opportunities

• Increasing Favorable Regulatory Approvals

Favorable regulatory approvals from agencies such as the U.S. FDA and the European Medicines Agency (EMA) are a significant driver for the growth of the bare metal stents market. In recent years, the FDA has approved several innovative bare metal stents, ensuring that patients have access to safe and effective treatment options. For instance, in 2020, the FDA approved the Orsiro® hybrid drug-eluting stent (DES), which has now become a widely used option alongside bare metal stents in coronary artery disease treatment. Regulatory agencies continue to set high standards for stent safety and effectiveness, which fosters greater trust among healthcare providers and patients. In addition, the EMA's approval of stent products such as the Medtronic Resolute Onyx™ bare metal stent has increased their availability in Europe. These approvals ensure the steady introduction of new and improved products to the market and expand the options available to physicians, helping to meet the growing demand for coronary artery interventions, thus contributing to the market's expansion.

• Increased Technological Advancements

Technological advancements in stent materials and designs are creating significant opportunities for growth in the bare metal stents market. Innovations such as the development of thinner, more flexible stents have improved the ease of insertion, reduced complications, and enhanced patient outcomes. For instance, the launch of the Abbott Supra™ Coronary Stent, which features a unique polymer-free design and improved flexibility, has made it easier for physicians to navigate complex coronary anatomies, reducing the risk of damage to blood vessels during insertion. These advanced stents are designed to minimize restenosis (re-narrowing of the artery), a common complication associated with traditional stents. In addition, the shift towards bioresorbable materials is opening up new avenues for market expansion. These advancements make stent procedures safer and more efficient and cater to the increasing demand for minimally invasive treatments. As more healthcare providers adopt these advanced technologies, the market for bare metal stents is expected to see substantial growth, presenting a valuable opportunity for both manufacturers and patients seeking improved cardiovascular care.

Restraints/Challenges

• Higher Risk of Restenosis

The higher risk of restenosis is a significant challenge for the bare metal stents (BMS) market, as these stents are more such asly to cause the re-narrowing of arteries compared to drug-eluting stents (DES). Restenosis can lead to repeat procedures, such as angioplasty or the need for additional stent placements, increasing healthcare costs and patient morbidity. For instance, in patients with complex or severe coronary artery disease, the risk of restenosis is more pronounced, making BMS a less favorable option. As a result, healthcare providers often prefer DES, which offer a lower rate of restenosis due to their drug coating that inhibits excessive tissue growth. This preference for DES over BMS limits the market growth for bare metal stents, particularly as physicians and patients seek longer-term solutions with fewer complications. The increased risk of restenosis, therefore, directly discourages the use of BMS and reinforces the market dominance of drug-eluting alternatives.

• Competition from Drug-Eluting Stents (DES)

Competition from drug-eluting stents (DES) presents a significant challenge for the bare metal stents (BMS) market, as DES provide superior clinical outcomes, particularly in reducing the risk of restenosis (re-narrowing of arteries). The drug coating on DES helps to prevent excessive tissue growth within the stent, offering better long-term effectiveness compared to BMS, which have a higher risk of restenosis and require additional procedures. For instance, in patients with complex coronary artery disease, the reduced such aslihood of restenosis with DES makes them the preferred choice, even though BMS are more affordable. As a result, BMS have seen a decline in demand, especially for patients who need more durable, long-term solutions. This shift towards DES has diminished the market share of BMS and highlighted the competitive advantage of DES, making it a key challenge for the bare metal stent market to maintain relevance and growth in the face of these superior alternatives.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Bare Metal Stents Market Scope

The market is segmented on the basis of product, and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Balloon Catheter
• Self-Expandable
• Metallic Stent
• Balloon-Expandable Stent

End Users

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories

Bare Metal Stents Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, and end users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bare metal stents market, driven by increasing lifestyle-related factors such as obesity and other cardiovascular diseases, including heart attacks, strokes, and ischemic heart diseases (IHD). The growing prevalence of coronary artery disease, coupled with a rise in percutaneous coronary interventions (PCI) procedures, is further fueling market growth. In addition, the increasing demand for minimally invasive procedures in the region is contributing to the dominance of North America in this market.

Asia-Pacific is anticipated to experience highest growth in the bare metal stents market, driven by an aging population with cardiovascular diseases, an increase in PCI procedures, and improvements in healthcare infrastructure in developing economies. In addition, growing healthcare awareness, better reimbursement options, and the lower manufacturing costs of coronary stents in this region are contributing to the market's expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Bare Metal Stents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Bare Metal Stents Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• Boston SciTech Inc. (U.S.)
• Medinol (Israel)
• iVascular S.L.U. (Spain)
• Elixir Medical (U.S.)
• InspireMD Inc. (U.S.)
• CIPUTRA69 (Not widely recognized; further details required)
• Hexacath (France)
• Medtronic (U.S.)
• Andramed GmbH (Germany)
• Cardinal Health (U.S.)
• OrbusNeich Medical Group Holdings Limited (Hong Kong)
• ENDOCOR GmbH & CO. KG (Germany)
• MicroPort Scientific Corporation (China)
• Amaranth Medical Analytics Pvt. Ltd. (India)
• Terumo Corporation (Japan)
• Meril Life Sciences Pvt. Ltd. (India)
• Alvimedica (Turkey)
• Biotronik (Germany)
• Arthesys (France)
• Lepumedical (France)

Latest Developments in Bare Metal Stents Market

• In September 2024, Uppsala University introduced a flexible stent aimed at reducing complications in coronary artery surgery. The stent was tested in the Infinity-Swedeheart study, which included 2,400 patients across 20 Swedish hospitals. The study compared this innovative stent with the traditional Resolute Onyx stent and holds potential to improve patient recovery and long-term outcomes in cardiac surgery
• In August 2024, Sahajanand Medical Technologies (SMT) completed patient enrollment for the Tuxedo 2 clinical trial in India. This pivotal trial is focused on assessing the safety and efficacy of the Supraflex Cruz Drug-Eluting Stent (DES) in diabetic patients suffering from multivessel coronary artery disease (CAD)
• In May 2024, Abbott launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. This advanced stent offers enhanced safety for complex cases and is designed to treat patients with blocked coronary arteries, contributing to improved outcomes in angioplasty procedures
• In March 2024, Silk Road Medical, Inc. launched the Tapered ENROUTE Transcarotid Stent System in the U.S., primarily for use in hospitals. The new tapered configurations are part of the company’s broader portfolio, which enhances the flexibility of its carotid solutions, providing physicians with more options to address individual patient anatomy
• In February 2021, Cardiovascular Systems Inc. announced a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary drug-coated balloons for use in drug-eluting stents

SKU-59435